S-1: cbdMD Files for Potential Resale of 5.1 Million Shares Following Convertible Note Issuance

cbdMD, Inc. has filed a registration statement for the potential resale of up to 5,138,890 shares of its common stock by selling shareholders, following a recent private placement involving convertible notes.

Summary

• cbdMD, Inc. has filed a Form S-1 registration statement with the SEC.
• The filing pertains to the potential resale of up to 5,138,890 shares of common stock.
• These shares are or will be held by selling shareholders who received them or will receive them upon conversion of convertible notes.
• The convertible notes were issued as part of a private placement that closed on February 1, 2024.
• The company will not receive any proceeds from the sale of these shares by the selling shareholders.
• The company's common stock is listed on the NYSE American under the symbol YCBD.
• On February 14, 2024, the last reported sale price of the common stock on the NYSE American was $0.64 per share.
• The selling shareholders may be considered underwriters and any profits they make may be considered underwriting commissions.
• The company recently launched its hempMD product line and expanded its retail reach into Sprouts Supermarkets.
• The company also launched a functional mushroom line of products under the ATRx brand.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is raising capital and expanding into new markets, the potential dilution and regulatory uncertainties create a balanced outlook.

Positives

• The company secured $1,250,000 in gross proceeds through a private placement, providing working capital.
• The company is actively working to simplify its capital structure, which it believes will unlock additional equity value.
• The company is expanding into new product categories, such as functional mushrooms, to diversify revenue streams.
• The company is focused on optimizing its product portfolio, right-sizing its cost structure, and investing in marketing to deliver positive earnings.
• The company has seen a strong increase in subscribers year over year since changing its e-commerce platform.
• The Paw CBD brand won another Pet Innovations award.

Negatives

• The company will not receive any proceeds from the resale of shares by the selling shareholders.
• The potential conversion of notes and preferred stock could cause substantial dilution to existing shareholders.
• The company is subject to continued listing standards of the NYSE American, and failure to satisfy these criteria may result in de-listing of its securities.
• The company was unable to get the required votes needed to approve the amendment to convert the Series A Preferred stock to common stock through a shareholder vote.

Risks

• Investing in the company's securities involves a high degree of risk, and investors could lose their entire investment.
• The company is subject to the continued listing standards of the NYSE American, and failure to satisfy these criteria may result in de-listing of its securities.
• The issuance of shares upon exercise of outstanding options, restricted stock awards and warrants, or the conversion of the Notes or Series A Convertible Preferred Stock may cause immediate and substantial dilution to existing shareholders.
• The lack of a clear regulatory framework has a negative impact and limits the opportunity for CBD companies that act with integrity and invest in responsible quality and safety standards.

Future Outlook

Management is focused on delivering positive earnings through optimizing the product portfolio, right-sizing the cost structure, and investing in marketing. The company is also expanding into new categories, such as functional mushrooms, to diversify revenue streams.

Management Comments

• Management continues to be very focused on delivering positive earnings through a combination of optimizing our product portfolio, right-sizing our cost structure and investing in marketing that will provide positive return on customer acquisition.
• Our goal is to simplify our capital structure and we believe it will help unlock additional equity value and open up more strategic activity for the Company.
• At our core, we believe in natural health and wellness solutions and we believe in the benefits derived from functional mushrooms in addition to hemp.

Industry Context

The company operates in the CBD and hemp-derived products industry, which is subject to evolving regulations and increasing competition. The company is expanding into functional mushrooms to diversify its product offerings and address regulatory hurdles in the CBD market.

Comparison to Industry Standards

• The document does not contain enough information to make a detailed comparison to industry standards.
• However, the company's focus on product diversification and cost optimization aligns with strategies employed by other companies in the competitive CBD and wellness market.
• Comparable companies in the CBD space include Charlotte's Web, CV Sciences, and Canopy Growth, though direct comparisons are limited without detailed financial data.

Stakeholder Impact

• Shareholders may experience dilution due to the potential conversion of notes and preferred stock.
• Employees may be affected by the company's efforts to right-size its cost structure.
• Customers may benefit from the company's expansion into new product categories and its focus on customer experience.

Next Steps

• The company needs to obtain shareholder approval for the issuance of shares exceeding 20% of outstanding common stock.
• The company will continue to focus on optimizing its product portfolio, right-sizing its cost structure, and investing in marketing.
• The company is working to open up additional channels and are in discussions with a large retailer to anchor the launch of 4 new SKUs under the ATRx brand during the balance of fiscal 2024.

Key Dates

Keywords

cbdMD, common stock, convertible notes, private placement, selling shareholders, YCBD, CBD, hemp, cannabinoids, dilution